Tags

Type your tag names separated by a space and hit enter

Improving oral pharmacologic treatment and management of type 2 diabetes.
Manag Care. 2004 Feb; 13(2):41-7.MC

Abstract

Type 2 diabetes and its associated complications impose a substantial burden on those affected by the disease and have a significant economic impact on the national health care system. Recent estimates indicate a substantial increase in diabetes prevalence in the United States in the past decade, with the largest increases occurring in minority populations. Although diet and exercise are important treatment components, they ultimately fail to control hyperglycemia in many patients. Most patients initially require oral pharmacologic therapy, and many will need multiple agents to stabilize and maintain glycemic control over time. Simplifying oral treatment regimens and reducing pill burden could improve patients' adherence to treatment substantially. Implementation of early and aggressive glycemic control along with appropriate monitoring can reduce the incidence of complications associated with diabetes, thereby improving patients' outcomes and ultimately decreasing health care costs. Toward these goals, the Diabetes Quality Improvement Project (now the National Quality Improvement Alliance) has developed measures designed to improve the care of patients with type 2 diabetes. These measures, along with new oral treatment options, may allow patients and their health care providers to achieve better glycemic control, improve adherence, and reduce the costs associated with this progressive and chronic disease.

Authors+Show Affiliations

Division of Diabetes and Endocrinology, Scripps Clinic, 10666 North Torrey Pines Rd., La Jolla, CA 92037, USA. gdailey@scrippsclinic.com

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15004930

Citation

Dailey, George E.. "Improving Oral Pharmacologic Treatment and Management of Type 2 Diabetes." Managed Care (Langhorne, Pa.), vol. 13, no. 2, 2004, pp. 41-7.
Dailey GE. Improving oral pharmacologic treatment and management of type 2 diabetes. Manag Care. 2004;13(2):41-7.
Dailey, G. E. (2004). Improving oral pharmacologic treatment and management of type 2 diabetes. Managed Care (Langhorne, Pa.), 13(2), 41-7.
Dailey GE. Improving Oral Pharmacologic Treatment and Management of Type 2 Diabetes. Manag Care. 2004;13(2):41-7. PubMed PMID: 15004930.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improving oral pharmacologic treatment and management of type 2 diabetes. A1 - Dailey,George E,3rd PY - 2004/3/10/pubmed PY - 2004/4/9/medline PY - 2004/3/10/entrez SP - 41 EP - 7 JF - Managed care (Langhorne, Pa.) JO - Manag Care VL - 13 IS - 2 N2 - Type 2 diabetes and its associated complications impose a substantial burden on those affected by the disease and have a significant economic impact on the national health care system. Recent estimates indicate a substantial increase in diabetes prevalence in the United States in the past decade, with the largest increases occurring in minority populations. Although diet and exercise are important treatment components, they ultimately fail to control hyperglycemia in many patients. Most patients initially require oral pharmacologic therapy, and many will need multiple agents to stabilize and maintain glycemic control over time. Simplifying oral treatment regimens and reducing pill burden could improve patients' adherence to treatment substantially. Implementation of early and aggressive glycemic control along with appropriate monitoring can reduce the incidence of complications associated with diabetes, thereby improving patients' outcomes and ultimately decreasing health care costs. Toward these goals, the Diabetes Quality Improvement Project (now the National Quality Improvement Alliance) has developed measures designed to improve the care of patients with type 2 diabetes. These measures, along with new oral treatment options, may allow patients and their health care providers to achieve better glycemic control, improve adherence, and reduce the costs associated with this progressive and chronic disease. SN - 1062-3388 UR - https://www.unboundmedicine.com/medline/citation/15004930/Improving_oral_pharmacologic_treatment_and_management_of_type_2_diabetes_ L2 - http://www.managedcaremag.com/linkout/2004/2/41 DB - PRIME DP - Unbound Medicine ER -